Bayer Adds Two Indications in China for Anticoagulant Xarelto

Bayer AG announced that the CFDA has approved Xarelto (rivaroxaban), a once-daily oral anticoagulant, for two new anti-clotting indications: strokes and deep vein thrombosis. Xarelto has been on the China market since 2009 to prevent clots following hip or knee replacement surgeries. Both of the new indications were tested in large global clinical trials. More details.... Stock Symbol: (XETRA: BAYN) Share this with colleagues: // //